University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Phillip Febbo

Phillip Febbo, M.D.

Genitourinary cancer specialist

Dr. Phillip G. Febbo is a medical oncologist who specializes in genitourinary cancer. He is co-director of the Prostate Cancer Program at UCSF Helen Diller Family Comprehensive Cancer Center. In his research, he studies prostate cancer and applied genomics.

Febbo received a medical degree at the University of California, San Francisco and completed a residency in internal medicine at Brigham and Women's Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute, both in Boston. He has won many awards including the American Society of Clinical Oncology, Young Investigator Award; CapCURE, Young Investigator Award; Prostate Cancer Foundation Award; and Department of Defense, Idea Development Award. He is a member of the American Society of Clinical Oncology, American Association for Cancer Research and American Society of Clinical Investigation. He is an associate professor of medicine at UCSF.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Phillip Febbo

Education

UCSF School of Medicine 1993

Residencies

Brigham and Women's Hospital, Internal Medicine 1996

Fellowships

Dana Farber Cancer Institute, Medical Oncology 1999

Selected Research and Publications

  1. Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate. 2013 May; 73(7):754-62.
  2. Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9.
  3. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012 Feb 14; 21(2):155-67.
  4. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 1; 118(19):4777-84.
  5. Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw. 2011 Dec; 9 Suppl 6:S1-16.
  6. Stewart SB, Baņez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol. 2012 Jan; 187(1):103-8.
  7. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011 Nov; 9 Suppl 5:S1-32; quiz S33.
  8. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2011 Jan; 17(1):135.
  9. Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG. Immune signatures predict prognosis in localized cancer. Cancer Invest. 2010 Aug; 28(7):765-73.
  10. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1; 16(11):3057-66.
  11. Balakumaran BS, Herbert JT, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy. Autophagy. 2010 Feb; 6(2):281-2.
  12. Foye A, Febbo PG. Cancer gene profiling in prostate cancer. Methods Mol Biol. 2010; 576:293-326.
  13. Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009 Oct 1; 69(19):7803-10.
  14. Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist. 2009 Aug; 14(8):816-27.
  15. Febbo PG. Genomic approaches to outcome prediction in prostate cancer. Cancer. 2009 Jul 1; 115(13 Suppl):3046-57.
  16. Febbo PG. Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer. J Clin Oncol. 2009 Jul 1; 27(19):3088-90.
  17. Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila). 2009 Jun; 2(6):557-65.
  18. Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell. 2009 Apr 10; 34(1):104-14.
  19. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 1; 101(7):519-32.
  20. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009 Apr 20; 27(12):2022-9.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2013 The Regents of The University of California